ClinicalTrials.gg
CompletedNCT07269756Updated Jun 29, 2026

A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects

A Phase 1 interventional study of HRS-7535 Tablets and Paracetamol Tablets in Obesity and Overweight, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd. — 8 open to participants now, 13 under way, 4 of them phase 3. Obesity · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
22nd of 24
40 · median 130
Started
2025
with 9 others
Phase 1
11 of 24
4 open now
Registered
17th of 24
by date

Among the 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd., this one is the 22nd largest by enrollment, is one of 10 that started in 2025, is one of 11 in phase 1, and was the 17th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This study is an open-label, fixed-sequence, self-controlled Phase I clinical trial conducted among obese or overweight subjects, with a planned enrollment of 40 adult subjects.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form prior to any study-related activities, understand the procedures and methods of the study, and agree to complete this study in strict accordance with the clinical study protocol;
  2. Males or females aged 18-50 years (inclusive);
  3. Weight ≥ 50.0 kg and \<100.0 kg, and (BMI) ≥26.0 kg/m2;
  4. Male subjects who are female with fertility or whose partners are female with fertility must have no plans to have children or donate sperm/eggs from the date of signing the informed consent form until one month after the last medication use, and voluntarily take effective measures (including for their partners).

Exclusion criteria

Exclusion Criteria:

  1. Those with a history of drug or food allergies, or those with an allergic constitution;
  2. History of inability to swallow, chronic diarrhea and intestinal obstruction, or the presence of multiple other factors that affect drug administration and absorption;
  3. History of diabetes (except gestational diabetes);
  4. Those with a history of severe hypoglycemia;
  5. There is a history of clinical gastric emptying abnormalities (such as gastric outlet obstruction) and severe chronic gastrointestinal diseases (such as inflammatory bowel disease, active ulcers) in the past;
  6. Those with a history or family history of medullary thyroid carcinoma, multiple endocrine adenomatosis type 2, acute or chronic pancreatitis, symptomatic gallbladder diseases or cholestasis;
  7. Any malignant tumor of the organ system has occurred within 5 years, regardless of whether there is evidence of local recurrence or . Local basal cell carcinoma of the skin, cervical carcinoma in situ and prostate carcinoma in situ are excluded;
  8. Those who have undergone any surgery within the six months prior to screening;
  9. Severe cardiovascular and cerebrovascular diseases have occurred within 6 months prior to screening, including but not limited to: heart failure ( grade II-IV), angina pectoris, stroke or , myocardial infarction, severe arrhythmia, or coronary artery bypass grafting or percutaneous coronary intervention, etc. And/or planned to undergo coronary, carotid or peripheral artery revascularization at the time of screening;
  10. Those who frequently consumed alcohol within the six months prior to the screening, that is, those who consumed more than 14 units of alcohol per week (1 unit = 360 mL of beer, or 45 mL of 40% alcohol spirits, or 100 mL of wine), and who could not stop using any alcoholic products during the trial period, and whose breath test for alcohol was positive;
  11. Those who have participated in any clinical trials of drugs or medical devices within the three months prior to screening (based on the intervention of the trial drugs or medical devices);
  12. Those who smoked more than five cigarettes per day in the three months prior to screening and were unable to stop using any tobacco products during the trial period;
  13. Those who have donated blood (or lost blood) within 3 months prior to screening with a blood donation (or blood loss) volume of ≥ 400 mL, or have received blood transfusion;
  14. Those who have experienced any acute disease that has been determined to have clinical significance by the researchers within one month prior to screening;
  15. Those who have received a vaccine within one month before screening or plan to receive a vaccine during the trial period;
  16. Those who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health supplements within 14 days prior to screening and/or baseline, and plan to take drugs or health supplements other than those tested in this study during the trial period;
  17. Having undergone gastrointestinal surgery that may cause malabsorption before screening, or having taken drugs that directly affect gastrointestinal peristalsis for a long time. For example: having undergone bariatric surgery or procedures (such as gastric banding), or having used weight-reducing drugs (including but not limited to orlistat) within 3 months prior to administration, or reporting a weight change of more than 5kg within 3 months prior to administration;
  18. During screening, a 12-lead (ECG) examination showed that the was ≥450 ms in males and ≥470 ms in females, or that the ECG had other abnormal conditions that the researcher judged to be of clinical significance;
  19. Those with a history of drug abuse, drug dependence (during consultation), or with a positive result in pre-administration urine drug abuse screening;
  20. Abnormal and examination results such as laboratory tests, physical examinations, vital signs, abdominal ultrasound, chest X-rays, etc;
  21. The Investigators considered the subjects to have other factors that made them unsuitable for participating in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Oral Medication Group

    Drug: HRS-7535 Tablets · Drug: Paracetamol Tablets · Drug: Digoxin Tablets · Drug: Rosuvastatin Calcium Tablets · Drug: Omeprazole Enteric-coated Capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum concentration (Cmax)

    Time frame: 63 days.

  2. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last)

    Time frame: 63 days.

  3. Area under the concentration-time curve from time zero to infinity (AUC0-inf)

    Time frame: 63 days.

Secondary outcomes

  1. Time of maximum concentration (Tmax)

    Pharmacokinetic parameters of HRS-7535.

    Time frame: 63 days.

  2. Area under the concentration-time curve from time zero to the end of the dosing interval tau (AUC0-tau)

    Pharmacokinetic parameters of HRS-7535.

    Time frame: 63 days.

  3. Elimination half-life (t1/2)

    Pharmacokinetic parameters of HRS-7535.

    Time frame: 63 days.

  4. Apparent clearance (CL/F)

    Pharmacokinetic parameters of HRS-7535.

    Time frame: 63 days.

  5. Apparent volume of distribution (Vz/F)

    Pharmacokinetic parameters of HRS-7535.

    Time frame: 63 days.

  6. Apparent volume of distribution (Vz/F)

    Pharmacokinetic parameters of Paracetamol, Digoxin, Rosuvastatin and Omeprazole.

    Time frame: 63 days.

  7. Apparent clearance (CL/F)

    Pharmacokinetic parameters of Paracetamol, Digoxin, Rosuvastatin and Omeprazole.

    Time frame: 63 days.

  8. Elimination half-life (t1/2)

    Pharmacokinetic parameters of Paracetamol, Digoxin, Rosuvastatin and Omeprazole.

    Time frame: 63 days.

  9. Area under the concentration-time curve from time zero to the end of the dosing interval tau (AUC0-tau)

    Pharmacokinetic parameters of Paracetamol, Digoxin, Rosuvastatin and Omeprazole.

    Time frame: 63 days.

  10. Time of maximum concentration (Tmax)

    Pharmacokinetic parameters of Paracetamol, Digoxin, Rosuvastatin and Omeprazole.

    Time frame: 63 days.

  11. Incidence of adverse events (AEs)

    Safety measures.

    Time frame: 70 days.

  12. Incidence of serious adverse events (SAEs)

    Safety measures.

    Time frame: 70 days.

07

Study locations

1 site
  • Suzhou Municipal Hospital
    Suzhou, Jiangsu 215000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Mar 2026, 3 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2025
First posted
Dec 8, 2025
StartActual
Dec 7, 2025
Primary completionActual
Mar 8, 2026
CompletionActual
Mar 8, 2026
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07269756
Responsible party
Sponsor
First posted
Dec 8, 2025
Start date
Dec 7, 2025
Primary completion
Mar 8, 2026
Completion
Mar 8, 2026
Last update
Jun 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-7535

Start the discussion